59702-07-7

Basic information

• Product Name: 1-Methylpiperazin-2-one
• Synonyms: 1-METHYL-PIPERAZIN-2-ONE;1-METHYL-PIPERAZINE-2-ONE;2-Piperazinone, 1-methyl-;1-Methylpiperazin-2-one ,98%;1-Methylpiperazin-2-one ,97%;-Methyl-piperazin-2-one;1-methylpiperazin-2-one(SALTDATA: HCl);1-Methyl-2-piperazinone
• CAS NO: 59702-07-7
• Molecular Formula: C₅H₁₀N₂O
• Molecular Weight: 114.15
• Mol File: 59702-07-7.mol

Chemical Properties

• Boiling Point: 242.12 °C at 760 mmHg
• Flash Point: 100.231 °C
• Appearance: /
• Density: 1.037 g/cm³
• Vapor Pressure: 0.035mmHg at 25°C
• Refractive Index: 1.461
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 7.42±0.20(Predicted)
• CAS DataBase Reference: 1-Methylpiperazin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methylpiperazin-2-one(59702-07-7)
• EPA Substance Registry System: 1-Methylpiperazin-2-one(59702-07-7)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 59702-07-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Production:
1-Methylpiperazin-2-one is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides.
Used in Solvent Applications:
As a solvent, 1-Methylpiperazin-2-one is employed in various chemical processes due to its ability to dissolve a wide range of substances, facilitating reactions and improving process efficiency.
Used in the Oil and Gas Industry:
1-Methylpiperazin-2-one is used as a polymerization inhibitor to prevent unwanted polymer formation in the production and processing of petroleum products, ensuring the stability and quality of these products.
1-Methylpiperazin-2-one is also used as a corrosion inhibitor in the oil and gas industry to protect metal surfaces from corrosion, extending the lifespan of equipment and reducing maintenance costs.

InChI:InChI=1/C5H10N2O/c1-7-3-2-6-4-5(7)8/h6H,2-4H2,1H3

Upstream product

• 851726-65-3 4-benzyloxycarbonyl-1-methyl-3,4-dihydropyrazin-2(1H)-one 
• 110-85-0 piperazine 
• 109384-27-2 1-methylpiperazin-2-one hydrochloride 
• 109384-26-1 1-tert-butoxycarbonyl-4-methyl-3-oxopiperazine 
• 851726-64-2 benzyl (2-((2,2-dimethoxyethyl)(methyl)amino)-2-oxoethyl)carbamate 
• 685520-31-4 4-methyl-3-oxopiperazine-1-carboxylic acid benzyl ester 

Downstream Products

• 98106-36-6 6-Fluoro-1-(4-fluoro-phenyl)-7-(4-methyl-3-oxo-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 344778-72-9 3-(2-fluorophenyl)-5-(1-methyl-2-oxopiperazin-4-yl)-[1,2,3]triazolo[1,5-a]quinazoline 
• 1202409-70-8 6-(3-fluorophenyl)-N-{(1S,3R)-3-[(4-methyl-3-oxopiperazin-1-yl)carbonyl]cyclopentyl}nicotinamide 
• 86291-02-3 4-(2-hydroxyethyl)-1-methylpiperazin-2-one 
• 1255339-28-6 1-methyl-4-[2-(4-{4-[3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperazin-1-yl}phenoxy)ethyl]piperazin-2-one 
• 851726-66-4 ethyl 8-(benzyloxy)-2-methyl-1-oxo-1,2,3,4-tetrahydro-pyrrolo[1,2-a]-pyrazine-7-carboxylate 
• 851726-92-6 ethyl 8-(benzyloxy)-6-bromo-2-methyl-1-oxo-1,2,3,4-tetrahydro-pyrrolo[1,2-a]-pyrazine-7-carboxylate 
• 869901-54-2 ethyl 6-acetyl-8-(benzyloxy)-2-methyl-1-oxo-1,2,3,4-tetrahydro-pyrrolo[1,2-a]-pyrazine-7-carboxylate 
• 870006-71-6 ethyl 6-(bromoacetyl)-8-(benzyloxy)-2-methyl-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-7-carboxylate 
• 870006-72-7 ethyl 8-(benzyloxy)-6-[(1,1-dioxido-1,2-thiazinan-2-yl)acetyl]-2-methyl-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-7-carboxylate 

Relevant articles and documents

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

Synthetic method of 4-(n-azetidin -2-3-)-1- one-methyl piperazinedione dihydrochloride (by machine translation)

The synthesis method provided by the invention, comprises 3 - the following steps: 4 - (of: reacting ;4) sodium hydride) - 1 - with tert-butyl carboxylate and methyl iodomethane, 3 - and. the. method disclosed by the invention, can be used for the reactio

Containing piperazinone quinazoline ketone PARP - 1/2 inhibitor and its preparation method, pharmaceutical composition and use thereof (by machine translation)

The invention discloses a new class of containing piperazinone quinazoline - 2, 4 (1 H, 3 H) - dione PARP - 1/2 inhibitor, and its preparation and pharmaceutical composition and use. Specifically, the invention relates to the general formula I shown containing of the piperazinone quinazoline - 2, 4 (1 H, 3 H) - dione derivatives and their pharmaceutically acceptable salt, and its preparation method, comprising one or more of the compounds of the composition, and the compounds in the preparation, the prevention and/or treatment with PARP - 1/2 of a disease associated with the use of the medicament. (by machine translation)

Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

A series of β-amino amide containing substituted piperazine-2-one derivatives was synthesized and evaluated as inhibitors of dipeptidyl pepdidase-4 (DPP-4) for the treatment of type 2 diabetes. As results of intensive SAR study of the series, (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl)- butanoyl]-3-(t-butoxymethyl)-piperazin-2-one (DA-1229) displayed potent DPP-4 inhibition pattern in several animal models, was selected for clinical development.

PYRAZOLE DERIVATIVE

A compound represented by Formula (I): wherein Ar1 represents Formula (II): Ar2 represents a 5- or 6-membered aromatic heterocyclic group which may be substituted; and X represents Formula (III): a salt thereof, or a solvate of the compound or the salt. A potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.

HIV INTEGRASE INHIBITORS

Substituted hydroxytetrahydropyrrolopyrazinone and substituted hydroxytetrahydro-pyrazolopyrazinone compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein R1, R2, R3, R

HIV INTEGRASE INHIBITORS

Hydroxy-substituted pyrazinopyrrolopyridazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

Hydroxy-substituted pyridopyrrolopyrazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I): (I) wherein a, b, A, B, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Piperazinonephenyloxazolidinone derivatives and their use as antibacterial agents

PCT No. PCT/GB97/00169 Sec. 371 Date Jul. 27, 1998 Sec. 102(e) Date Jul. 27, 1998 PCT Filed Jan. 21, 1997 PCT Pub. No. WO97/27188 PCT Pub. Date Jul. 31, 1997The invention concerns a compound of formula (I) wherein: R1 is of the formula -NHC(=O)(1-4C)alkyl, -NHS(O)n(1-4C)alkyl wherein n is 0, 1 or 2 or R1 is hydroxy; R2 and R3 are independently hydrogen or fluoro; R4 is hydrogen, methyl, ethyl or oxo; R5 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or of the formula R6(CH2)m- wherein either m is 1-4 and R6 is, for example, trifluoromethyl, difluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkyl S(O)p- wherein p is 0, 1 or 2, (1-6C)alkanoyloxy, di-(+E,uns N+EE -(1-4C)alkyl)amino, +E,uns N+EE -((1-4C)alkyl)(1-4C)alkanoylamino, cyano, carboxy, (1-4C)alkoxycarbonyl, carbamoyl, di-(+E,uns N+EE -(1-4C)alkyl)carbamoyl, +E,uns N+EE -((1-4C)alkyl)(1-4C)alkanesulphonamido, +E,uns N+EE 1-((1-4C)alkyl)-di-(+E,uns N+EE 3-(1-4C)alkyl)ureido, or of the formula -OC(=O)NR7(R8) or -N(R9)SO2NR7(R8) wherein R7 and R8 are independently hydrogen or (1-4C)alkyl and R9 is (1-4C)alkyl; or m is 2-4 and R6 is, for example, hydroxy, (1-4C)alkanoylamino, amino, (1-4C)alkylamino, (1-4C)alkanesulphonamido, ureido, di-(+E,uns N+EE 3-(1-4C)alkyl)ureido or of the formula -NHSO2NR7(R8); and pharmaceutically-acceptable salts thereof; processes for their preparation; pharmaceutical compositions containing them and their use as antibacterial agents.

New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same

A compound of the formula: STR1 wherein R1 is lower alkyl optionally substituted with a substituent selected from the group consisting of acyl, hydroxy, lower alkoxy, aryl, lower alkylthio and a group of the formula: STR2 in which R5 is hydrogen or acyl and R6 is hydrogen or lower alkyl; aryl; or amino optionally substituted with substituent(s) selected from the group consisting of lower alkyl and acyl; and R2 is hydrogen or lower alkyl; or R1 and R2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with substituent(s) selected from the group consisting of lower alkyl, hydroxy(lower )alkyl, lower alkoxy(lower)alkyl, acyl(lower)alkyl, oxo and acyl; R3 is hydrogen or lower alkyl; and R4 is lower alkyl; and its pharmaceutically acceptable salt, processes for the preparation thereof and pharmaceutical composition comprising the same.